Pfizervs.Zoetis
PFE vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Pfizer is about 5.1× larger than Zoetis by market cap; Zoetis trades at the lower P/E (11.5 vs 35.2); year to date, Pfizer leads (+12.3% vs −38.7%).
Side by side
| PFE | ZTS | |
|---|---|---|
| Market cap | $152B | $30.2B |
| Price | $28.57 | $77.29 |
| Today | +2.1% | +0.2% |
| Return YTD | +12.3% | −38.7% |
| Return 1Y | +8.1% | −50.7% |
| P/E | 35.2 | 11.5 |
| P/S | 2.4 | 3.2 |
| P/B | 1.8 | 9.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →ZoetisZTS
Spun out of Pfizer in 2013 to sell animal medicines and vaccines. Simparica handles parasites while Librela and Solensia treat pain, with pets on one side of the business and livestock on the other.
Full ZTS profile →More PFE & ZTS comparisons
Other head-to-heads in the Big pharma segment.